SCHEMBL10242902

SCHEMBL10242902

CCCCNC(=O)Cc1cccc(-c2ccco2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.51
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
HPGD P15428 3/20 0.49
GAA P10253 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
ALDH1A1 P00352 4/20 0.47
POLB P06746 3/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
ALOX15 P16050 1/20 0.47
CASP1 P29466 1/20 0.47
BLM P54132 1/20 0.47
CASP7 P55210 1/20 0.47
KMT2A Q03164 1/20 0.47
MCL1 Q07820 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10242915 0.93 PRMT6 (0.53) PRMT6HPGDGAATRPV1ALDH1A1
SCHEMBL10242931 0.87 PRMT6 (0.56) PRMT6HPGDALDH1A1POLBKDM4E
SCHEMBL12250924 0.81 PRMT6 (0.52) PRMT6HPGDALDH1A1POLBKDM4E
SCHEMBL12303899 0.81 PRMT6 (0.51) PRMT6HPGDGAAALDH1A1KDM4E
SCHEMBL10242939 0.80 SMN1; SMN2 (0.65) HPGDGAAALDH1A1POLBKDM4E
SCHEMBL10242926 0.78 ALDH1A1 (0.49) HPGDGAAALDH1A1POLBKDM4E
SCHEMBL10243023 0.78 PTPN7 (0.64) HPGDALDH1A1POLBKDM4EMEN1
SCHEMBL10242942 0.78 PTGS2 (0.54)
SCHEMBL10242930 0.78 PRMT6 (0.60) PRMT6HPGDALDH1A1POLBKDM4E
SCHEMBL10242917 0.77 ALDH1A1 (0.49) PRMT6HPGDGAAALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 PRMT6 1751/4885CA1 3677/4885CA2 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.